01 Procurement
Tender overview
- Buyer
- NHS England
- Status
- Complete
- Procurement method
- Direct award
- Category
- Not supplied
- CPV classification
- Not supplied
- Tender period
- Not supplied — Not supplied
Description
Embedding blood group genotyping into routine practice. The primary objective (benefit) of doing so is to ensure patients with rare blood disorders have a minimise risk of adverse reactions through access to blood group genotyping. Due to delays arising from administrative and operational circumstances, NHS England awarded this contract to commencing 25 June 2025 until 31 March 2026.
This page represents one OCDS contracting process. Notices can be revised over time. Values may be estimates, award values or contract values and should be read with their displayed stage and date.
02 Awards and contracts
Published award records
Blood Group Genotyping for Sickle Cell and Thalassaemia
- Awarded
- 14 May 2025
- Award value
- £140,671
- Suppliers
- 1
- Signed contract
- 9 June 2026
03 Organisations
Buyers, suppliers and other parties
NHS England
Wellington House, 133-135 Waterloo Rd, London, UKI45, SE1 8UG, United Kingdom
GB-PPON PDPT-3135-BWWYNHSBT
500 North Bristol Park, Filton, Bristol, UKK12, BS34 7QH, United Kingdom
GB-NHS T1460Companies House links appear only for explicit GB-COH identifiers. BritDB does not create company links from a similar name or address.
04 Provenance
Source for this process
Contains public sector information licensed under the Open Government Licence v3.0. Official external links are available only on the source transition page.